Neutralizing antibody

Immunoassays for detecting, tracking, and testing SARS-CoV-2 antibody responses

President Biden’s planned rollout of additional COVID-19 vaccine doses is set to begin next week, but questions remain about who should get them.

Mix-and-match shots could simplify vaccine rollout and stimulate more-robust immune responses. Ongoing clinical trials will soon give answers.

A treatment of two monoclonal antibodies against SARS-CoV-2 is ninefold less effective in the lab against the B.1.351 variant than against the dominant version of the virus.

A blood biobank allows scientists to study the immune responses to the coronavirus among infected Biogen employees and their contacts.

A memory B cell response to Zika virus in dengue-infected patients produced antibodies that were poorly neutralizing in vitro and instead enhanced infection.

A family of broadly neutralizing antibodies from a chronically infected donor provides a schematic for designing vaccines and treatments that target multiple strains of the virus.

Type I interferon organizes several immune mechanisms to suppress B cell responses to a chronic viral infection.

Techniques for faster discovery and isolation of human monoclonal antibodies